uniQure Shares Surge Following FDA Official's Departure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy QURE?
Source: Benzinga
- Significant Stock Surge: uniQure's shares surged 31.39% to $18.75 in premarket trading following the announcement of FDA's biologics division head Vinay Prasad's resignation, extending a 33.99% increase from Friday, indicating strong market optimism about the company's future prospects.
- Regulatory Decision Controversy: During Prasad's tenure, he faced criticism for the FDA's rejection of uniQure's Huntington's disease gene therapy application, as the agency recommended a prospective randomized controlled study, adding regulatory uncertainty that could impact uniQure's market outlook.
- Clinical Trial Challenges: The FDA previously indicated that uniQure could pursue accelerated approval without a placebo control due to difficulties in enrolling Huntington's disease patients, reflecting regulatory flexibility for rare diseases, yet this has sparked ongoing debates about clinical trial design.
- Strong Market Reaction: Following the news of Prasad's departure, uniQure's shares reportedly jumped as much as 70% in after-hours trading, reflecting investor expectations for a potential easing of tensions between the company and the FDA, which could pave the way for future product approvals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.990
Low
33.00
Averages
49.88
High
70.00
Current: 17.990
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Stock Surges 36% Despite FDA Criticism
- FDA Criticism Impact: Despite a US FDA official criticizing uniQure on March 5 for a “distorted or manipulated comparison” in its Huntington's disease asset AMT-130 study, the stock surged approximately 36% in premarket trading, indicating market confidence in its future prospects.
- Stock Price Recovery: Following the FDA official's comments, uniQure's share price closed up about 18% on March 5 and added another approximately 34% on March 6, reflecting investor optimism regarding the company's outlook.
- Clinical Trial Requirement: The FDA has requested uniQure to conduct a phase 3 trial, which may increase R&D costs in the short term but also provides an opportunity for the company to further validate its product's efficacy, potentially enhancing market acceptance in the long run.
- Leadership Change Impact: The stock price increase is partly attributed to the upcoming departure of Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, in April, with the market generally viewing this change as potentially improving the company's relationship with the FDA, thereby benefiting the approval process for AMT-130.
See More
H.C. Wainwright Optimistic on uniQure's Gene Therapy Prospects
- Regulatory Shift: H.C. Wainwright noted that the departure of Vinay Prasad, head of the FDA's division of vaccines and gene therapies, will 'reshape the regulatory calculus' for uniQure's Huntington's disease gene therapy AMT-130, potentially accelerating its approval process.
- Price Target Increase: Analysts at Chardan nearly doubled their price target for uniQure from $16 to $31 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance, particularly in light of Prasad's departure.
- Stock Price Surge: Following a 26% increase on Monday, uniQure's stock rose nearly 7% in pre-market trading on Tuesday, reflecting market optimism regarding its gene therapy, especially after positive analyst commentary.
- Investor Sentiment Recovery: Although uniQure's stock is down 25% year-to-date, it has risen 45% over the past 12 months, indicating a bullish sentiment among retail investors on social media, highlighting the market's focus on its gene therapy prospects.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V., concerning stock purchases made between September 24 and October 31, 2025, or risk losing their right to claim.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, a drop of over 49%, from $67.69 on October 31 to $34.29, significantly undermining investor confidence and market perception of the company.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which has severely impacted investor trust and may lead to substantial liability for the company.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, indicating the firm's commitment to seeking recoveries for economic losses stemming from corporate misconduct.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, which has shaken investor confidence.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission is unclear, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, allowing them to represent other investors in the legal proceedings and protect their rights effectively.
- Legal Consultation Opportunity: Kessler Topaz Meltzer & Check, LLP offers free case evaluations and encourages investors to reach out for more information on their legal rights and potential recovery options, ensuring that investors incur no costs in the process.
See More
Reminder for uniQure Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS for the number of settlements in 2017, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information; participation in the class action incurs no upfront costs, ensuring investor rights are protected.
See More
Leadership Change at uniQure Seen as Positive Development
- Leadership Impact: Mizuho upgraded uniQure (QURE) from ‘Neutral’ to ‘Outperform’ following the announcement of Prasad's departure, suggesting that this change could reopen pathways for AMT-130 based on existing data, enhancing regulatory flexibility.
- Regulatory Landscape Shift: H.C. Wainwright noted that Prasad's exit 'reshapes the regulatory calculus' for AMT-130, maintaining confidence in the existing dataset and broader pipeline, indicating that QURE shares are poised for a value inflection.
- Positive Market Reaction: Following the news of Prasad's departure, QURE stock closed 1.5% higher on Tuesday and gained an additional 1% in after-hours trading, reflecting a bullish sentiment among investors.
- Long-Term Growth Potential: With a 56% increase in stock price over the past 12 months, the market appears optimistic about uniQure's future, particularly in light of potential new opportunities for AMT-130's approval post-Prasad's exit.
See More
uniQure Stock Surges 36% Despite FDA Criticism
- FDA Criticism Impact: Despite a US FDA official criticizing uniQure on March 5 for a “distorted or manipulated comparison” in its Huntington's disease asset AMT-130 study, the stock surged approximately 36% in premarket trading, indicating market confidence in its future prospects.
- Stock Price Recovery: Following the FDA official's comments, uniQure's share price closed up about 18% on March 5 and added another approximately 34% on March 6, reflecting investor optimism regarding the company's outlook.
- Clinical Trial Requirement: The FDA has requested uniQure to conduct a phase 3 trial, which may increase R&D costs in the short term but also provides an opportunity for the company to further validate its product's efficacy, potentially enhancing market acceptance in the long run.
- Leadership Change Impact: The stock price increase is partly attributed to the upcoming departure of Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, in April, with the market generally viewing this change as potentially improving the company's relationship with the FDA, thereby benefiting the approval process for AMT-130.
See More
H.C. Wainwright Optimistic on uniQure's Gene Therapy Prospects
- Regulatory Shift: H.C. Wainwright noted that the departure of Vinay Prasad, head of the FDA's division of vaccines and gene therapies, will 'reshape the regulatory calculus' for uniQure's Huntington's disease gene therapy AMT-130, potentially accelerating its approval process.
- Price Target Increase: Analysts at Chardan nearly doubled their price target for uniQure from $16 to $31 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance, particularly in light of Prasad's departure.
- Stock Price Surge: Following a 26% increase on Monday, uniQure's stock rose nearly 7% in pre-market trading on Tuesday, reflecting market optimism regarding its gene therapy, especially after positive analyst commentary.
- Investor Sentiment Recovery: Although uniQure's stock is down 25% year-to-date, it has risen 45% over the past 12 months, indicating a bullish sentiment among retail investors on social media, highlighting the market's focus on its gene therapy prospects.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 13, 2026, to participate in the securities class action against uniQure N.V., concerning stock purchases made between September 24 and October 31, 2025, or risk losing their right to claim.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, a drop of over 49%, from $67.69 on October 31 to $34.29, significantly undermining investor confidence and market perception of the company.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which has severely impacted investor trust and may lead to substantial liability for the company.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, indicating the firm's commitment to seeking recoveries for economic losses stemming from corporate misconduct.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, which has shaken investor confidence.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission is unclear, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, allowing them to represent other investors in the legal proceedings and protect their rights effectively.
- Legal Consultation Opportunity: Kessler Topaz Meltzer & Check, LLP offers free case evaluations and encourages investors to reach out for more information on their legal rights and potential recovery options, ensuring that investors incur no costs in the process.
See More
Reminder for uniQure Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS for the number of settlements in 2017, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information; participation in the class action incurs no upfront costs, ensuring investor rights are protected.
See More
Leadership Change at uniQure Seen as Positive Development
- Leadership Impact: Mizuho upgraded uniQure (QURE) from ‘Neutral’ to ‘Outperform’ following the announcement of Prasad's departure, suggesting that this change could reopen pathways for AMT-130 based on existing data, enhancing regulatory flexibility.
- Regulatory Landscape Shift: H.C. Wainwright noted that Prasad's exit 'reshapes the regulatory calculus' for AMT-130, maintaining confidence in the existing dataset and broader pipeline, indicating that QURE shares are poised for a value inflection.
- Positive Market Reaction: Following the news of Prasad's departure, QURE stock closed 1.5% higher on Tuesday and gained an additional 1% in after-hours trading, reflecting a bullish sentiment among investors.
- Long-Term Growth Potential: With a 56% increase in stock price over the past 12 months, the market appears optimistic about uniQure's future, particularly in light of potential new opportunities for AMT-130's approval post-Prasad's exit.
See More
